This pattern prevails when IDCs are pooled as well as when they are separated into hormone positive, HER2 amplified or triple-negative categories, indicating that loss of Sprouty4 is not an event specifically tied to a single clinical subtype of breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.